Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cerebrotendinous xanthomatosis].

V M Berginer

    Zhurnal Nevropatologii I Psikhiatrii Imeni S.S. Korsakova (Moscow, Russia : 1952)
    |January 1, 1992
    PubMed
    Summary
    This summary is machine-generated.

    Cerebrotendinous xanthomatosis (CTX) is a rare genetic lipid disorder. Chenodeoxycholic acid therapy helps reduce cholestanol buildup and improve neurological symptoms in patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Neurological aspects of the David-Goliath battle: restriction in the giant's visual field.

    The Israel Medical Association journal : IMAJ·2000
    Same author

    Aspects of cerebrotendinous xanthomatosis (CTX).

    Neurologia i neurochirurgia polska·1996
    Same author

    Historical aspects of cerebrotendinous xanthomatosis (CTX).

    Journal of the history of the neurosciences·1995
    Same author

    Cerebrotendinous xanthomatosis in the Israeli Druze: molecular genetics and phenotypic characteristics.

    American journal of human genetics·1994
    Same author

    Molecular genetics of cerebrotendinous xanthomatosis in Jews of north African origin.

    Journal of lipid research·1994
    Same author

    Magnetic resonance imaging in cerebrotendinous xanthomatosis: a prospective clinical and neuroradiological study.

    Journal of the neurological sciences·1994
    Same journal

    [Various indicators of serotonin metabolism in the cerebrospinal fluid of patients with neurasthenia and cerebral arachnoiditis].

    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)·1992
    Same journal

    [Molecular-genetic analysis of Huntington chorea (review of the foreign literature)].

    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)·1992
    Same journal

    [Various indicators of the hormonal profile in patients with neuroses after psychopharmacotherapy and functional test with sinacten].

    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)·1992
    Same journal

    [Use of plasmapheresis in the complex treatment of patients with endogenous psychoses].

    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)·1992
    Same journal

    [Use of intravascular laser irradiation of blood in the treatment of drug-resistant forms of schizophrenia].

    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)·1992
    Same journal

    [Approach to the optimal therapy of the psycho-autonomic syndrome].

    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)·1992
    See all related articles

    Area of Science:

    • Biochemistry
    • Genetics
    • Metabolic Disorders

    Context:

    • Cerebrotendinous xanthomatosis (CTX) is a rare inherited disorder of lipid metabolism.
    • It results from impaired bile acid synthesis, leading to cholestanol accumulation.
    • Clinical manifestations include neurological deficits, xanthomas, and early-onset cataracts.

    Purpose:

    • To investigate the therapeutic potential of chenodeoxycholic acid (CDCA) in CTX.
    • To evaluate the effect of CDCA on cholestanol levels and clinical symptoms.

    Summary:

    • CTX is characterized by defective bile acid synthesis, causing accumulation of cholestanol, a cholesterol derivative.
    • This leads to progressive neurological dysfunction, tendon xanthomas, cataracts, and other health issues.
    • Replacement therapy with chenodeoxycholic acid (750 mg/day) normalizes bile acid synthesis, reducing cholestanol levels and improving neurological function.

    Related Experiment Videos

    Impact:

    • Chenodeoxycholic acid therapy offers a promising treatment for Cerebrotendinous xanthomatosis.
    • This approach can mitigate the severe neurological and systemic complications associated with CTX.
    • It highlights the importance of bile acid replacement in managing lipid storage diseases.